الفهرس Only 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Systemic lupus erythematosus (SLE) is a complex disease characterized by numerous autoantibodies and clinical involvement in multiple organ systems. Autoantibodies are usually present in serum for years before the onset of clinical disease. Autoimmunity begins with a limited number of autoantibodies and evolves to become progressively more diverse. are Humoral immune responses and the production of autoantibodies regulated in part by signaling through B cell Ag receptors. Autoimmunity and immune responses are further regulated or tuned” by signal transduction molecules that amplify or inhibitAg fine receptor signaling during responses to self and foreign Ags. These regulatory interrelated cell surface molecules include a subset of functionally CD22, and their intracellular signaling receptors, such as CD19 and Lyn, Btk, Vav, and the SHP1 protein tyrosine components including phosphatase.
This study was carried out to elaborate on : The relationship of the B cell surface markers CD19, CD20 and CD22 to indices of SLE activity, the relation of these markers to laboratory determinants of SLE activity, the impact of therapy on B cell surface markers and a pilot study of SLE patients followed up in Pediatric Departement Menoufiya University Hospital. 114